About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More


ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Study identifier: NCT01306032
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)


Triple-negative breast cancer which has progressed following at least one line of therapy. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan.

Type of study:

Randomized, Phase II trial for patients with triple-negative breast cancer 


Patients will be randomized to receive either oral cyclophosphamide alone or oral cyclophosphamide in combination with ABT-888.

Study sites:

For all study sites, please contact:

Deborah E. Allen, R.N. (301) 402-5640 allendeb@mail.nih.gov


University of California, Davis     
Davis, California, 95616


H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida,  33612


University of Chicago     
Chicago, Illinois, 60637


National Institutes of Health Clinical Center, 9000 Rockville Pike   
Bethesda, Maryland, United States, 20892


Mayo Clinic, Rochester  
Rochester, Minnesota, 55905


University of Nebraska Med. Ctr. Eppley Cancer Ctr.
Omaha, Nebraska, 68198-5950

New York

Montefiore Medical Center
Bronx, New York, 10467

Memorial Sloan Kettering Cancer Center
New York, New York, 10021


Ohio State University      
Columbus, Ohio, United States, 43210-1240


MD Anderson Cancer Center
Houston, Texas, 77030-4096


Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9 


Page updated 03/21/11  

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org